US2011104193A1PendingUtilityA1
Combination neisserial compositions
Assignee: NOVARTIS VACCINES & DIAGNOSTICPriority: May 19, 1999Filed: Dec 27, 2010Published: May 5, 2011
Est. expiryMay 19, 2019(expired)· nominal 20-yr term from priority
A61P 37/04A61P 31/04A61K 39/095C07K 14/22A61K 2039/53A61K 39/39A61K 39/02A61K 2039/55505A61K 38/164A61K 2039/70A61K 39/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.
Claims
exact text as granted — not AI-modified1 : An immunogenic composition comprising a first substantially purified polypeptide comprising a first amino acid sequence selected from (i) SEQ ID NO: 3518; (ii) a sequence having at least 90% sequence identity to SEQ ID NO: 3518; and (iii) a fragment of 8 or more contiguous amino acids from SEQ ID NO: 3518; and a second substantially purified polypeptide comprising a second amino acid sequence selected from (a) SEQ ID NO: 3926; (b) a sequence having at least 90% sequence identity to SEQ ID NO: 3926; and (c) a fragment of 8 or more contiguous amino acids from SEQ ID NO: 3926.
2 . The immunogenic composition of claim 1 wherein the first amino acid sequence selected from (i) SEQ ID NO: 3518; (ii) a sequence having at least 95% sequence identity to SEQ ID NO: 3518; and (iii) a fragment of 14 or more contiguous amino acids from SEQ ID NO: 3518; and a second substantially purified polypeptide comprising a second amino acid sequence selected from (a) SEQ ID NO: 3926; (b) a sequence having at least 95% sequence identity to SEQ ID NO: 3926; and (c) a fragment of 14 or more contiguous amino acids from SEQ ID NO: 3926.
3 . The immunogenic composition of claim 1 wherein the first amino acid sequence selected from (i) SEQ ID NO: 3518; and (ii) a fragment of 20 or more contiguous amino acids from SEQ ID NO: 3518; and a second substantially purified polypeptide comprising a second amino acid sequence selected from (a) SEQ ID NO: 3926; and (b) a fragment of 20 or more contiguous amino acids from SEQ ID NO: 3926.Join the waitlist — get patent alerts
Track US2011104193A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.